PharmaCorp Rx (PCRX) Q2 2026 earnings summary

Executive summary

• Revenue for Q2 2026 rose 75.8% year-over-year to $7.7 million, driven by organic growth and acquisitions.

• Gross profit increased 78.2% year-over-year to $3.1 million, with gross margin improving to 40.3%.

• Net income reached $0.12 million in Q2 2026, reversing a net loss of $0.39 million in Q2 2025.

• Same-store sales grew 3.8% and same-store prescription sales rose 5.2% year-over-year.

Financial highlights

• Adjusted EBITDA (Pre-IFRS 16, 4-Wall basis) for Q2 2026 was $1.7 million, up 148.7% from Q2 2025.

• Cash position as of June 30, 2026, was $24.0 million, compared to $25.9 million at year-end 2025.

• Year-over-year improvements attributed to higher prescription volumes, front-of-store sales, and increased pharmacy ownership (six vs. three locations).

Outlook and guidance

• Management highlights ongoing momentum in acquisition and integration strategy, with nine pharmacy acquisitions closed in July and another in August, bringing the total to 16 pharmacies.

• Forward-looking statements emphasize continued focus on acquiring and integrating community pharmacies across Canada.